Conference: [AAIC 2026](/events/aaic-2026) | Dates: July 12-15, 2026 | Location: Excel London, UK
Overview
flowchart TD
events_aaic_2026_prevention_tr["AAIC 2026: Prevention Trials"]
events_aaic_2026_prevention_tr["Conference"]
events_aaic_2026_prevention_tr -->|"related to"| events_aaic_2026_prevention_tr
style events_aaic_2026_prevention_tr fill:#81c784,stroke:#333,color:#000
events_aaic_2026_prevention_tr["Dates"]
events_aaic_2026_prevention_tr -->|"related to"| events_aaic_2026_prevention_tr
style events_aaic_2026_prevention_tr fill:#81c784,stroke:#333,color:#000
events_aaic_2026_prevention_tr["July"]
events_aaic_2026_prevention_tr -->|"related to"| events_aaic_2026_prevention_tr
style events_aaic_2026_prevention_tr fill:#81c784,stroke:#333,color:#000
events_aaic_2026_prevention_tr["Location"]
events_aaic_2026_prevention_tr -->|"related to"| events_aaic_2026_prevention_tr
style events_aaic_2026_prevention_tr fill:#81c784,stroke:#333,color:#000
style events_aaic_2026_prevention_tr fill:#4fc3f7,stroke:#333,color:#000
Prevention trials represent a critical frontier in [Alzheimer's disease](/diseases/alzheimers-disease) research, aiming to intervene before clinical symptoms appear. AAIC 2026 features extensive programming on prevention strategies, including pharmacological and lifestyle interventions, genetic risk reduction, and population-level prevention approaches["@rakesh2024"].
Primary Prevention Trials
Anti-Amyloid Prevention ... Conference: [AAIC 2026](/events/aaic-2026) | Dates: July 12-15, 2026 | Location: Excel London, UK
Overview
Mermaid diagram (expand to render)
Prevention trials represent a critical frontier in [Alzheimer's disease](/diseases/alzheimers-disease) research, aiming to intervene before clinical symptoms appear. AAIC 2026 features extensive programming on prevention strategies, including pharmacological and lifestyle interventions, genetic risk reduction, and population-level prevention approaches["@rakesh2024"].
Primary Prevention Trials
Anti-Amyloid Prevention
Autosomal Dominant Alzheimer's Disease (ADAD)
DIAN-TU : Updates on tau-targeted and amyloid-targeted armsAPI ADAD : Colombian kindred prevention programGeneration Study : [APP](/entities/app-protein) and presenilin mutation carriersSporadic AD Prevention
A4 Study : Anti-amyloid therapy in preclinical ADLEARN Study : Natural history in preclinical ADEXERT : Exercise intervention in cognitively normal adultsMulti-Domain Interventions
FINGER Trial : Finnish Geriatric Intervention Study[MAPT](/proteins/tau) : Multidomain Alzheimer Preventive TrialPOINTER : US-based multidomain interventionSecondary Prevention Trials
Biomarker-Positive Preclinical AD
TRAILBLAZER-ALZ 3 : [Donanemab](/entities/donanemab) in preclinical ADAHEAD 3-45 : [Lecanemab](/entities/lecanemab) in preclinical AD with elevated amyloidCognitively Normal with Amyloid : Various anti-amyloid approachesVascular Cognitive Impairment Prevention
SPRINT-MIND : Blood pressure control and cognitive outcomesACTC-EMERGE : Vascular contributions to dementia preventionRisk Factor Modification
Modifiable Risk Factors The [Lancet Commission on dementia prevention](/mechanisms/lifestyle-factors-dementia-prevention) identifies 12 modifiable risk factors:
Hearing loss : Hearing aid use and social engagementLess education : Cognitive reserve buildingTraumatic brain injury : Prevention and managementHypertension : Blood pressure controlAlcohol : Moderate consumptionObesity : Weight managementSmoking : Smoking cessationDepression : Treatment and preventionSocial isolation : Community engagementPhysical inactivity : Exercise recommendationsDiabetes : Metabolic managementSleep : Sleep hygiene and disorder treatment
Lifestyle Interventions
Physical Exercise
Aerobic exercise and cognitive benefits
Resistance training effects
Combined exercise modalities
Cognitive Training
Speed of processing training
Memory and executive function
Computerized vs. traditional approaches
Diet
[MIND Diet](/mechanisms/dietary-factors-neuroprotection): Mediterranean-DASH Intervention
Ketogenic approaches
Time-restricted eating
Special Populations
Early-Onset AD
Down Syndrome : Alzheimer's prevention in trisomy 21Autosomal Dominant : Genetic counseling and preventionDiverse Populations
African American communities : Inclusion in prevention trialsHispanic/Latino populations : Addressing health disparitiesAPOE4 carriers : Targeted prevention strategiesBiomarker Endpoints in Prevention
Amyloid PET
Centiloid standardization
Threshold determination for intervention
Longitudinal amyloid changes
Tau PET
Temporal lobe tau as endpoint
Tau progression rates
Correlation with cognitive decline
Fluid Biomarkers
[p-tau217](/proteins/tau): Preclinical detection
[p-tau181](/proteins/tau): Disease progression
[GFAP](/proteins/gfap): Astrocyte reactivity
[NFL](/proteins/nfl): Neurodegeneration
Notable Sessions
Symposia
"Update on DIAN-TU: Lessons Learned and Future Directions"
"Lifestyle Prevention: Evidence and Implementation"
"Biomarker Endpoints in Prevention Trials"
Workshops
"Recruitment Strategies for Prevention Trials"
"Statistical Methods for Slow Decline Endpoints"
Related NeuroWiki Content
[Alzheimer's Disease Prevention](/research/alzheimers-prevention)
[Risk Factors for AD](/research/ad-risk-factors)
[Lifestyle Factors in Dementia](/mechanisms/lifestyle-factors-dementia-prevention)
[APOE Gene](/genes/apoe)
[Biomarkers Overview](/research/biomarkers-alzheimers)
See Also
[AAIC 2026 Conference](/events/aaic-2026)
[AAIC 2026: Early Detection](/events/aaic-2026/early-detection)
[AAIC 2026: Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)
[Clinical Trials Index](/clinical-trials/alzheimers-trials)
References
[Rakesh G, et al., Prevention of Alzheimer's disease: A review. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00856-9)
[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 (2023)](https://doi.org/10.1056/NEJMoa2212948)
[McDade E, et al., Donanemab in Early Alzheimer's Disease. N Engl J Med. 2024 (2024)](https://doi.org/10.1056/NEJMoa2305030)
[Stern Y, et al., White Paper: Maximal life. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00788-1) Show full description